

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	4669955
<b>Application Number:</b>	10698099
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	7805
<b>Title of Invention:</b>	Prevention and treatment of synucleinopathic disease
<b>First Named Inventor/Applicant Name:</b>	Dale B. Schenk
<b>Customer Number:</b>	20350
<b>Filer:</b>	Rosemarie L. Celli/Tina Trieu
<b>Filer Authorized By:</b>	Rosemarie L. Celli
<b>Attorney Docket Number:</b>	015270-008930US
<b>Receipt Date:</b>	23-JAN-2009
<b>Filing Date:</b>	31-OCT-2003
<b>Time Stamp:</b>	19:47:14
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part/.zip	Pages (if appl.)
1	Foreign Reference	227-WO0160794A2.pdf	2087535 139865Gd9f9He1c1c729d4f1f9357b7fa2e6d6 d77	no	55

**Warnings:**

**Information:**

2	Foreign Reference	228-WO0160794A3.pdf	142902 e0f0c0d607bf05468312e3c08f51345 4928	no	3
---	-------------------	---------------------	---	----	---

**Warnings:****Information:**

3	Foreign Reference	220-WO03045128A2.pdf	8086079 a67ac2f02b20fcabfb1a5c0b7004041cfef3 6d40	no	265
---	-------------------	----------------------	---	----	-----

**Warnings:****Information:**

4	Foreign Reference	221-WO03045128A3.pdf	288170 2091374b032e55d4829c4cc5793d2ec 5721	no	6
---	-------------------	----------------------	---	----	---

**Warnings:****Information:**

5	Foreign Reference	235-WO03000714A2.pdf	601845 a0ee56717923eeefbb6989f338441e18ef 0341	no	12
---	-------------------	----------------------	--	----	----

**Warnings:****Information:**

6	Foreign Reference	236-WO03000714A3.pdf	126176 c0ffcb406eb5818ee69ab0ced7a01b0fe 5871	no	2
---	-------------------	----------------------	---	----	---

**Warnings:****Information:**

7	Foreign Reference	222-WO08103472A2.pdf	6759680 2f567907bd72125384941cc6898d5f7 b9a	no	135
---	-------------------	----------------------	---	----	-----

**Warnings:****Information:**

8	NPL Documents	226-AndersonJBC281-40-29739_2006.pdf	2205701 0x09011d527e5e790b1cd9bc554be52fc 97dc	no	14
---	---------------	--------------------------------------	--	----	----

**Warnings:****Information:**

9	NPL Documents	240-AlvesDaCosta_.pdf	677046 f13730e9fa1fb2a4ccce28eb1b4f0f359 0a1e	no	8
---	---------------	-----------------------	---	----	---

**Warnings:****Information:**

10	NPL Documents	224-CHILCOTE_Comparisonofalpha synucleinAbstract.pdf	73698 e661e61302f18e9043e3e19d6241f316e033a4 6d11	no	2
----	---------------	---	---	----	---

**Warnings:****Information:**

11	NPL Documents	241-Casadesus_TheEstrogenMyth_2006.pdf	513347 5418d047cfc9f513be95211bc0a9d30e9d53e	no	8
<b>Warnings:</b>					

**Information:**

12	NPL Documents	83-Clelandisomerization.pdf	711697 a1711240ab2946e1a5a08a9601ef97c5de48945	no	7
<b>Warnings:</b>					

**Information:**

13	NPL Documents	87-Demattos_peripheralantibody_2001.pdf	1402878 ff0bb696aa14712ae2941c73sec059840a7c52	no	6
<b>Warnings:</b>					

**Information:**

14	NPL Documents	237-EP037830083-3_EuroSupplSearch.pdf	407998 417b9a7908bb62794d1c18299f9d659fb61e06015e	no	11
<b>Warnings:</b>					

**Information:**

15	NPL Documents	238-EP05814041-9_SupplEuroSearchReport.pdf	1237320 e08199f3bed91a6a0bbceef9b22eff61aaf057	no	26
<b>Warnings:</b>					

**Information:**

16	NPL Documents	104-FRIEDLAND_MOLNEUROLOGY_1994.pdf	584220 a0299d75c72c3110d3d659d276991cb7983ef	no	7
<b>Warnings:</b>					

**Information:**

17	NPL Documents	242-JanewayTravers_IMMUNObio_1997.pdf	918196 016d671c994b625628dd6d940f52e825a5240e	no	5
<b>Warnings:</b>					

**Information:**

18	NPL Documents	229-Hashimoto_BetaSynucleinInhibitsAlpha.PDF	575287 31db9f9172c65bd8e02ac18e9a0a7bcaed994b3	no	6
<b>Warnings:</b>					

**Information:**

19	NPL Documents	233-Heiser_InhibitionofHuntingtinFibrillogenesis_2000.PDF	381220 1-e0ff97a671214c3ba92c94187a221f33e44	no	3
<b>Warnings:</b>					

**Information:**

20	NPL Documents	232-Lecerf_HumanSingleChainFV_2001.PDF	326703 0/18/63d9994e13618c98ac26a76e75f E9f	no	3
<b>Warnings:</b>					

**Information:**

21	NPL Documents	126-Lee_HumanAlphaSyn.pdf	677836 5a62b440d57994610654147024d70849 cfa	no	6
<b>Warnings:</b>					

**Information:**

22	NPL Documents	225-Lee_TrunctedAlphaAbstract.pdf	32849 5d9a19b73d19c8c4911593d9eb0fc5-2bc 8fb1	no	2
<b>Warnings:</b>					

**Information:**

23	NPL Documents	243-Perrin_EpitopeMapping_Abstract.pdf	444367 2b61fa0f7eb499b2675f2bd6dc1bf523aa 35c8	no	4
<b>Warnings:</b>					

**Information:**

24	NPL Documents	234-Rochet_Inhibitionoffibrillization_2000.PDF	453068 9a54ff2c3a925c078be48c6bf02/c7ff0 d8	no	4
<b>Warnings:</b>					

**Information:**

25	NPL Documents	244-Sidhu_DoesAlphaSynuclein_2004.pdf	1199334 36ff6d11e2baad1b91a223798f58794eaf 465c	no	11
<b>Warnings:</b>					

**Information:**

26	NPL Documents	245-Spillantini_AlphaSynucleinInLewyBodies_1997.pdf	240936 d6fbfe6ddde4fd5c14656c8be1de745edcc1 c1789	no	2
<b>Warnings:</b>					

**Information:**

27	NPL Documents	246-Takeda_AbnormalAccum_1998.pdf	428192 cadff9d2120cc494b629b105cc2e9f1e40fa7 ad9e	no	6
<b>Warnings:</b>					

**Information:**

28	NPL Documents	247-Tofaris_PhysiologicalProperties.pdf	729672 f11ccfbfe238947e7era/194718130sub/99 9629	no	8
<b>Warnings:</b>					

**Information:**

29	NPL Documents	223-TofarisJBC278-45-44405_2003.pdf	340308 B6ba6094c3c99c71f462386217d4b45e ec24	no	7		
<b>Warnings:</b>							
<b>Information:</b>							
30	NPL Documents	231-Wanker_ProtienAggregationinHuntingtonsandParkinsonsDis2000.PDF	360972 B6ba6094c3c99c71f462386217d4b45e ec24	no	3		
<b>Warnings:</b>							
<b>Information:</b>							
31	NPL Documents	230-Windsch_DevelopmentOfANewTreatment_2002.PDF	324397 B6ba6094c3c99c71f462386217d4b45e ec24	no	4		
<b>Warnings:</b>							
<b>Information:</b>							
32		015270-008930US_SIDS_to247_2009-01-23.PDF	300501 B6ba609112b724603c48357d46b421058 ec24	yes	7		
<b>Multipart Description/PDF files in .zip description</b>							
<b>Document Description</b>			<b>Start</b>	<b>End</b>			
Information Disclosure Statement Letter			1	3			
Information Disclosure Statement (IDS) Filed (SB/08)			4	7			
<b>Warnings:</b>							
<b>Information:</b>							
<b>Total Files Size (in bytes):</b>				33642860			
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p>							
<p><b>New Applications Under 35 U.S.C. 111</b>  If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p>							
<p><b>National Stage of an International Application under 35 U.S.C. 371</b>  If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>							
<p><b>New International Application Filed with the USPTO as a Receiving Office</b>  If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>							